Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's ...

Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $59.00.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high estimate of $70.00 and a low estimate of $39.00. Observing a downward ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a Neutral recommendation. Analyst Price Forecast Suggests 95.52% Upside As of ...

Learn more about whether Alvotech or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.